

Industrial Pharmacy II

As per the latest syllabus prescribed by Pharmacy Council of India for Bachelor of Pharmacy Course would help in bridging the existing gap of long needed demand for budding pharmacy technocrats, academicians and pharmacists, especially the budding professionals of pharmacy. It will serve as an excellent textbook for semester VII BPharm students.

Gaurav Agarwal MPharm, PhD is currently Dean, Faculty of Pharmacy, RP Indraprastha Institute of Technology (RP Educational Trust), Karnal. To his credit are numerous projects and publications. He has worked on taste masking techniques at F&D Department, IPCA Labs, Mumbai. He has an excellent track record in academic institutions of high repute like IFTM, Moradabad, and SGIT, Ghaziabad, and is actively engaged in teaching, research, administration and service to pharmacy profession. He has written well known textbooks like "Pharmaceutics I, Pharmaceutics II, Pharmaceutical Technology I, Pharmaceutical Technology II, Pharmacy Practice and Drug Regulatory Affairs, all published by CBSPD.



Jyoti Ghangas MPharm is currently Assistant Professor, Faculty of Pharmacy, RP Indraprastha Institute of Technology (RP Educational Trust), Karnal. During her research she has worked on generic drug approval submissions in ASEAN countries, and worked on various projects related to drug approval submissions in regulated and semi-regulated countries. She has won many awards in international and national conferences. She has field experience of working under NRHM for more than 3 years. She is actively engaged in review and research work related to drug regulatory affairs.



CBS Publishers & Distributors Pvt Ltd

4819/XI, Prahlad Street, 24 Ansari Road, Daryaganj, New Delhi 110 002, India

E-mail: delhi@cbspd.com, cbspubs@airtelmail.in; Website: www.cbspd.com

New Delhi | Bengaluru | Chennai | Kochi | Kolkata | Mumbai

Bhopal | Bhubaneswar | Hyderabad | Jharkhand | Nagpur | Patna | Pune | Uttarakhand | Dhaka (Bangladesh) | Kathmandu (Nepal)



QR code to access online CBS Catalogue

ISBN: 978-93-89688-52-8



Industrial Pharmacy II

Agarwal
Ghangas



Industrial Pharmacy II

As per the latest syllabus prescribed by Pharmacy Council of India for Bachelor of Pharmacy Course

Gaurav Agarwal
Jyoti Ghangas



Dedicated to Education

CBS Publishers & Distributors Pvt Ltd



Industrial Pharmacy II

As per the latest syllabus prescribed by
Pharmacy Council of India
for Bachelor of Pharmacy Course

Industrial Pharmacy II

As per the latest syllabus prescribed by
Pharmacy Council of India
for Bachelor of Pharmacy Course

Gaurav Agarwal

MPharm (BITS–Pilani) PhD
Dean, Faculty of Pharmacy
RP Inderaprashta Institute of Technology
Karnal, Haryana

Jyoti Ghangas

MPharm (Amity University, Noida)
Assistant Professor, Faculty of Pharmacy
RP Inderaprashta Institute of Technology
Karnal, Haryana



CBS Publishers & Distributors Pvt Ltd

New Delhi • Bengaluru • Chennai • Kochi • Kolkata • Mumbai
Bhopal • Bhubaneswar • Hyderabad • Jharkhand • Nagpur • Patna • Pune
Uttarakhand • Dhaka (Bangladesh) • Kathmandu (Nepal)

Industrial Pharmacy II

Disclaimer

Science and technology are constantly changing fields. New research and experience broaden the scope of information and knowledge. The authors have tried their best in giving information available to them while preparing the material for this book. Although, all efforts have been made to ensure optimum accuracy of the material, yet it is quite possible that some errors might have been left uncorrected. The publisher, the printer and the authors will not be held responsible for any inadvertent errors or inaccuracies.

The authors of the book have taken all the reasonable care to ensure that the contents of book do not violate any existing copyright or other intellectual property rights of any person in any manner. In the event the authors had/have been unable to track any source and if any copyright has been inadvertently infringed, do notify the publisher in writing for corrective measures.

ISBN: 978-93-89688-52-8

Copyright © Authors and Publisher

First Edition: 2020

All rights reserved. No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system without permission, in writing, from the authors and the publisher.

Published by Satish Kumar Jain and produced by Varun Jain for

CBS Publishers & Distributors Pvt Ltd

4819/XI Prahlad Street, 24 Ansari Road, Daryaganj, New Delhi 110 002, India.

Ph: 23289259, 23266861, 23266867

Fax: 011-23243014

Website: www.cbspd.com

e-mail: delhi@cbspd.com; cbspubs@airtelmail.in.

Corporate Office: 204 FIE, Industrial Area, Patparganj, Delhi 110 092

Ph: 4934 4934

Fax: 4934 4935

e-mail: publishing@cbspd.com; publicity@cbspd.com

Branches

- **Bengaluru:** Seema House 2975, 17th Cross, K.R. Road, Banasankari 2nd Stage, Bengaluru 560 070, Karnataka
Ph: +91-80-26771678/79 Fax: +91-80-26771680 e-mail: bangalore@cbspd.com
- **Chennai:** 7, Subbaraya Street, Shenoy Nagar, Chennai 600 030, Tamil Nadu
Ph: +91-44-26680620, 26681266 Fax: +91-44-42032115 e-mail: chennai@cbspd.com
- **Kochi:** 42/1325, 1326, Power House Road, Opp KSEB, Power House, Ernakulam 682 018, Kochi, Kerala
Ph: +91-484-4059061-67 Fax: +91-484-4059065 e-mail: kochi@cbspd.com
- **Kolkata:** 6/B, Ground Floor, Rameswar Shaw Road, Kolkata-700 014, West Bengal
Ph: +91-33-22891126, 22891127, 22891128 e-mail: kolkata@cbspd.com
- **Mumbai:** 83-C, Dr E Moses Road, Worli, Mumbai-400018, Maharashtra
Ph: +91-22-24902340/41 Fax: +91-22-24902342 e-mail: mumbai@cbspd.com

Representatives

- | | | | | | |
|--------------------|--------------|----------------------|--------------|-----------------------------|--------------|
| • Bhopal | 0-8319310552 | • Bhubaneswar | 0-9911037372 | • Hyderabad | 0-9885175004 |
| • Jharkhand | 0-9811541605 | • Nagpur | 0-9421945513 | • Patna | 0-9334159340 |
| • Pune | 0-9623451994 | • Uttarakhand | 0-9716462459 | • Dhaka (Bangladesh) | 01912-003485 |
- **Kathmandu (Nepal)** 977-9818742655

Printed at: India Binding House, Noida, UP, India

*to
my father*



Sh. Ram Kumar Chhangas

—Jyoti Chhangas

Preface

The book *Industrial Pharmacy II* is designed specifically as per PCI (Pharmacy Council of India) BPharmacy Seventh Semester students. The book covers the entire syllabus prescribed by PCI Course Regulation, 2014 in a very simple and precise manner to meet the demanding needs of the pharmacy aspirants. This book covers wide areas and contains a comprehensive description of current existing knowledge of drug regulatory affairs. The text not only deals with the basic concepts but also emphasizes technical and practical aspects of the subject. The book is primarily intended as a textbook for students of pharmacy for degree and masters courses in drug regulatory affairs. The book is also of great help for technocrats who want to pursue career in regulatory affairs department in pharmaceutical industry. Being an interdisciplinary subject, it is today covering a wide range of interest among the students, teaching and industry people. Taking this increasing interest into account, this book gives a comprehensive introduction to the subject.

The book contains numerous specimens, vivid illustrations, tables, diagrams and flow diagrams to present the ideas. The distinguishing feature is a summary of all the units at the end of each unit. The structure and the content of the book have changed to reflect modern thinking and current university curricula throughout the world. In spite of great care there might be some mistakes and deficiencies. We will be grateful for giving suggestions to improve. So go through the content and do mail to me at gbitsian@rediffmail.com.

Gaurav Agarwal
Jyoti Ghangas

Acknowledgements

It is a moment of great pleasure and immense satisfaction for me to express deep gratitude and gratefulness to my father Er VK Agarwal and my mother Smt Asha Agarwal for inspiring me to bring out this book.

I am especially thankful to Shri RP Singal Ji, Chairman, RP Educational Trust, for his all time support and encouragement. My special thanks to Er Bharat Singal, and Anuj Singal, Secretary, RP Educational Trust, for inspiring me to bring out this book. I am indebted to Shri DL Mittal, Director, RPIIT Technical and Medical Campus, for his motivation.

I am also thankful to CBS Publishers and Distributors. I would like to put on record the sincere efforts of Mr YN Arjuna (Senior Vice President Publishing, Editorial and Publicity) and his team comprising of Ms Ritu Chawla (GM Production), Mr Parmod Kumar (DTP Operator) and Mr Rohan Prasad (Graphic Designer), for bringing out the book in the present form.

My completion of this project could not have been accomplished without the support of my loving daughter Shreya and son Vaidish who have allowed me time away from the writing and research work.

Last but not the least, I express my love to my wife Dr Shilpi for her caring, motivating and supportive nature. Her encouragement was always there when the times got rough. It was a great comfort and relief that she kept me away from our household activities during the entire tenure of writing and research work.

To my numerous students, whom I cannot possibly name individually, I thanks for their class interactions which have been the guiding spirit in selection of the subject matter and its logical arrangement.

Gaurav Agarwal

Acknowledgements

I would like to express my gratitude to Dr Gaurav Agarwal, Dean, Faculty of Pharmacy, RPIIT, for believing in me and giving me this opportunity to create something which will help the students in the years to come. It would not have been possible without his constant motivation and support.

I express my gratefulness to CBS Publishers and Distributors for giving me this opportunity.

I shall always be thankful and indebted to all my teachers, especially Dr Upendra Nagaich and Dr Neha Jain, who gave me all that I have today. I would like to thank my colleagues for supporting me in this endeavour.

I would like to appreciate the critical eyes and viewpoints of my husband Sumit Anand for reading early drafts and advising me at every step. He equally deserves the credit for early and logical completion of this work. I convey my heartiest gratitude and thanks for always being so supportive.

Any attempt at any level cannot be satisfactorily completed without the support and guidance of family members. I would like to thank my mother-in-law Smt Anuradha Sharma who helped me a lot from time to time in making this project distinctive by imparting her teaching skills despite her busy schedules, my father-in-law Sh. Shyam Narayan Sharma who gave me different ideas in making this project unique.

Special thanks and gratitude to my mother Smt Premwati Ghangas for being the one who supports me, inspires me and loves me. I am grateful to my uncle Advocate Sh. Rajbir Ghangas for inspiring me. I extend my sincere word of thanks to Sujata Anand, Shobhit Anand, Pooja Anand and Aashish Ghangas who have always been a constant support. Last but not the least, I express profound love to sweet children of my family Shorya, Surya and Shakti who always act as stress reliever for me with their innocent smile.

I have learned a lot from my students, and they deserve an equal credit for the insights that helped create this book. I hope students will appreciate this book.

Jyoti Ghangas

Syllabus Prescribed by Pharmacy Council of India for Bachelor of Pharmacy Course

BP 702 T. INDUSTRIAL PHARMACY II (Theory)

45 Hours

Scope: This course is designed to impart fundamental knowledge on pharmaceutical product development and translation from laboratory to market

Objectives: Upon completion of the course, the student shall be able to:

1. Know the process of pilot plant and scale up of pharmaceutical dosage forms
2. Understand the process of technology transfer from lab scale to commercial batch
3. Know different Laws and Acts that regulate pharmaceutical industry
4. Understand the approval process and regulatory requirements for drug products

Course Content

UNIT 1

10 Hours

Pilot plant scale up techniques: General considerations-including significance of personnel requirements, space requirements, raw materials, pilot plant scale up considerations for solids, liquid orals, semi solids and relevant documentation, SUPAC guidelines, Introduction to platform technology

UNIT 2

10 Hours

Technology development and transfer: WHO guidelines for technology transfer(TT): Terminology, technology transfer protocol, quality risk management, transfer from R & D to production (process, packaging and cleaning), granularity of TT process (API, excipients, finished products, packaging materials) documentation, premises and equipment, qualification and validation, quality control, analytical method transfer, approved regulatory bodies and agencies, commercialization—practical aspects and problems (case studies), TT agencies in India—APCTD, NRDC, TIFAC, BCIL, TBSE/SIDBI; TT related documentation—confidentiality agreement, licensing, MoUs, legal issues

UNIT 3

10 Hours

Regulatory affairs: Introduction, historical overview of regulatory affairs, regulatory authorities, role of regulatory affairs department, responsibility of regulatory affairs professionals

Regulatory requirements for drug approval: Drug development teams, non-clinical drug development, pharmacology, drug metabolism and toxicology, general considerations of investigational new drug (IND) application, investigator's brochure (IB) and new drug application (NDA), clinical research/BE studies, clinical research protocols, biostatistics in pharmaceutical product development, data presentation for FDA submissions, management of clinical studies.

UNIT 4

08 Hours

Quality management systems: Quality management & certifications: Concept of quality, total quality management, quality by design (QbD), six sigma concept, out of specifications (OOS), change control, introduction to ISO 9000 series of quality systems standards, ISO 14000, NABL, GLP

UNIT 5

07 Hours

Indian regulatory requirements: Central Drug Standard Control Organization (CDSCO) and State Licensing Authority: Organization, Responsibilities, Certificate of Pharmaceutical Product (COPP), Regulatory requirements and approval procedures for new drugs.

Recommended Books: Latest Editions

1. Regulatory Affairs from Wikipedia, the free encyclopedia modified on 7th April available at http://en.wikipedia.org/wiki/Regulatory_Affairs.
2. International Regulatory Affairs Updates, 2005. available at <http://www.iraup.com/about.php>
3. Douglas J Pisano and David S. Mantus. Text book of FDA Regulatory Affairs A Guide for Prescription Drugs, Medical Devices, and Biologics, Second Edition.
4. Regulatory Affairs brought by learning plus, inc. available at <http://www.cgmp.com/ra.htm>.

Contents

Preface

vii

UNIT 1: Pilot-Plant Scale-up Techniques

1. Introduction to Pilot-Plant and Scale-up	2
1.1 Plant	2
1.2 Pilot-Plant	2
1.2.1 Reasons for Conducting Pilot-Plant Studies	3
1.2.2 Objectives of Pilot-Plant	3
1.2.3 Pilot-Plant Operations	4
1.3 Scale-up	5
1.3.1 Need of Scale-up	5
1.3.2 Steps in Scale-up	5
1.3.3 Objectives of Scale-up	6
1.3.4 Relation between Pilot-Plant and Scale-up	6
Long Answer Type Questions	7
Short Answer Type Questions	7
Objective Type Questions	7
2. General Considerations and Pilot-Plant Considerations for Different Dosage Forms	9
2.1 General Considerations	9
2.1.1 Reporting Responsibilities	9
2.1.2 Personnel Requirement	9
2.1.3 Space Requirements	10
2.1.4 Review of the Formula	11
2.1.5 Raw Materials	11
2.1.6 Equipment	11
2.1.7 Production Rate	11
2.1.8 Process Evaluation	11
2.1.9 Preparation of Master Manufacturing Procedures	12
2.1.10 Product Stability and Uniformity	13
2.1.11 Good Manufacturing Practices (GMP) Considerations	13
2.1.12 Transfer of Analytical Methods to Quality Assurance	13
2.2 Pilot-Plant Scale-up Considerations for Solids (Tablets)	13
2.3 Pilot-Plant Scale-up Considerations for Oral Liquids	18
2.4 Pilot-Plant Scale-up Considerations for Semisolids	20
2.5 Documentation	21
Long Answer Type Questions	23
Short Answer Type Questions	23
Objective Type Questions	23

3. SUPAC Guidelines and Platform Technology **25**

- 3.1 Purpose of Guidance 25
- 3.2 Evolution of SUPAC Guidance 25
- 3.3 Terminologies used in Guidance Document 26
- 3.4 Level of Changes 28
- 3.5 Type of Changes 28
- 3.6 Introduction to Platform Technology 37
 - Long Answer Type Questions 39
 - Short Answer Type Questions 39
 - Objective Type Questions 39
 - Summary 41

UNIT 2: Technology Development and Transfer**4. Technology Development and Transfer** **50**

- 4.1 Technology 50
- 4.2 Technology Development 50
- 4.3 Technology Transfer 50
- 4.4 Technology Transfer in Pharmaceutical Sciences 51
 - 4.4.1 Reasons for Technology Transfer 54
 - 4.4.2 Types of Technology Transfer 55
 - 4.4.3 Methods of Technology Transfer 56
 - Long Answer Type Questions 57
 - Short Answer Type Questions 57
 - Objective Type Questions 57

5. WHO Guidelines for Transfer of Technology **60**

- 5.1 Introduction 60
- 5.2 Transfer of Technology (TOT) as per WHO 60
- 5.3 Scope of WHO Guidelines for TOT 62
- 5.4 Terminologies Source 62
- 5.5 Organisation and Management 66
- 5.6 Quality Risk Management 68
- 5.7 QRM Application in Pharmaceuticals 72
- 5.8 Transfer from R&D to Production (Process, Packaging and Cleaning) and Granularity of TT Process (API, Excipients, Finished Products, Packaging Material) 74
- 5.9 Analytical Method Transfer 79
- 5.10 Premises and Equipment 81
- 5.11 Documentation 84
- 5.12 Qualification and Validation 84
 - Long Answer Type Questions 85
 - Short Answer Type Questions 85
 - Objective Type Questions 85

6. Regulation of Transfer of Technology **87**

- 6.1 Authorities and Agencies Involved in TOT 87
- 6.2 Problems Faced During Commercialisation 89
- 6.3 Case Studies of Technology Transfer 90
- 6.4 TOT Agencies in India 91
 - 6.4.1 APCTT 91
 - 6.4.2 NRDC 93
 - 6.4.3 TIFAC (Technology Information Forecasting and Assessment Council) 95
 - 6.4.4 BCIL (Biotech Consortium India Limited) 97
 - 6.4.5 TBSE (Technology Bureau for Small Enterprises)/SIDBI (Small Industries Development Bank of India) 98
- 6.5 TOT Related Documentation 99
 - 6.5.1 Confidentiality Agreements 99
 - 6.5.2 Licensing 100
 - 6.5.3 MoU 102
 - 6.5.4 Legal Issues 103
 - Long Answer Type Questions 104
 - Short Answer Type Questions 104
 - Objective Type Questions 104
 - Summary 107

UNIT 3: Regulatory Affairs and Regulatory Requirements for Drug Approval

7. Regulatory Affairs and its Role **114**

- 7.1 Introduction 114
- 7.2 Historical Overview of Regulatory Affairs 115
- 7.3 Regulatory Authorities 116
- 7.4 Role of Regulatory Affairs Department 117
- 7.5 Responsibility of Regulatory Affairs Professionals 119
 - Long Answer Type Questions 120
 - Short Answer Type Questions 120
 - Objective Type Questions 120

8. Drug Development and Non-Clinical Studies **122**

- 8.1 Drug Development Teams 122
- 8.2 Non-clinical Drug Development 124
- 8.3 Toxicology 126
- 8.4 Drug Metabolism 126
 - Long Answer Type Questions 128
 - Short Answer Type Questions 128
 - Objective Type Questions 128

9. INDA and NDA	130
9.1 General Considerations of Investigational New Drug (IND) Application	130
9.2 Investigator's Brochure (IB)	131
9.3 New Drug Application (NDA)	132
9.4 Clinical Research/BE (Bioequivalence) Studies	134
9.5 Biostatistics in Pharmaceutical Product Development	136
9.6 Data Presentation for FDA Submissions	138
9.7 Management of Clinical Studies	139
Long Answer Type Questions	139
Short Answer Type Questions	140
Objective Type Questions	140
Summary	142

UNIT 4: Quality Management Systems

10. Quality and Related Concepts	150
10.1 Concept of Quality	150
10.2 Quality Control	155
10.3 Quality Assurance	156
10.4 Comparison Between Quality Control and Quality Assurance	156
Long Answer Type Questions	157
Short Answer Type Questions	157
Objective Type Questions	157
11. Total Quality Management and Other Quality Management Systems	159
11.1 Total Quality Management (TQM)	159
11.1.1 Origin of TQM	159
11.1.2 Characteristics of TQM	159
11.1.3 Principles of TQM	160
11.1.4 Key Elements of TQM	160
11.1.5 Main Objective of TQM: Continuous Improvement	161
11.1.6 Importance of TQM in the Pharmaceutical Industry	163
11.2 Quality by Design	164
11.2.1 Designing of Product/Process as per QbD Has Following Requirements	164
11.2.2 Benefits of QbD: QbD Helps in	165
11.2.3 Scope of QbD	165
11.2.4 Steps in Quality by Design Approach	165
11.2.5 Importance of Quality by Design in Pharmaceuticals	168

11.3 Six Sigma Concept	169
11.3.1 Characteristics of Six Sigma	169
11.3.2 Objectives of Six Sigma	170
11.3.3 Levels of Six Sigma	170
11.3.4 Six Sigma in Pharmaceuticals	171
11.4 Out of Specifications	171
11.4.1 Reasons for OOS	171
11.4.2 OOS Investigation	172
11.5 Change Control	174
11.5.1 Elements of Change Control	175
11.5.2 Classification of Changes	175
11.5.3 Motives of Change Control	175
11.5.4 Barriers in the Way of Effective Change Control	176
11.5.5 Regulatory Concerns/Requirement for Changes	176
Long Answer Type Questions	176
Short Answer Type Questions	176
Objective Type Questions	177
12. ISO Series, NABL and GLP	180
12.1 ISO 9000 Series	180
12.1.1 Standards within ISO 9000	181
12.1.2 Quality Principles	181
12.1.3 Steps in Obtaining ISO 9000 Series Certification	182
12.1.4 Advantages of Obtaining ISO 9000 Certification	182
12.1.5 Barriers in Implementing Efficient ISO 9000 Guidelines in an Organisation	182
12.2 ISO 14000 Series	183
12.2.1 Aim of ISO 14000 Series (as per ISO)	183
12.2.2 Model of ISO 14000 Series	184
12.3 GLP: Good Laboratory Practice	185
12.3.1 History	185
12.3.2 Scope of GLP	186
12.3.3 Fundamentals of GLP	186
12.3.4 Objectives of GLP	187
12.4 National Accreditation Board for Testing and Calibration Laboratories (NABL)	187
12.4.1 NABL Vision	187
12.4.2 NABL Mission	187
12.4.3 Achievements of NABL (As per the Official Website of NABL)	188
12.4.4 Scope of NABL Accreditation	188
12.4.5 Benefits of Accreditation	189
Long Answer Type Questions	190
Short Answer Type Questions	190
Objective Type Questions	190
Summary	193

UNIT 5: Indian Regulatory Requirements

13. Central and State Drug Regulatory Authority of India	206
13.1 Drug Regulatory Authority	206
13.2 Central Drug Standard Control Organisation (CDSCO)	208
13.3 State Licensing Authorities (SLA)	212
Long Answer Type Questions	213
Short Answer Type Questions	213
Objective Type Questions	213
14. CTD and New Drug Approval Process in India	215
14.1 Common Technical Document	215
14.2 Certificate of Pharmaceutical Product (COPP)	217
14.3 New Drug Approval in India	218
Requirements for New Drug Approval	220
Long Answer Type Questions	221
Short Answer Type Questions	221
Objective Type Questions	222
Summary	224
<i>Index</i>	229